Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014352 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
A Phase 2 study of Prostate Cancer and Thromboembolism, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00014352 is a Phase 2 study of Prostate Cancer and Thromboembolism that has completed, run by Memorial Sloan Kettering Cancer Center. The trial reports 1 study location across 1 state.
The verdict
NCT00014352, a Phase 2 study of Prostate Cancer and Thromboembolism, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Anticoagulant drugs such as warfarin may reduce the risk of blood clots. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus warfarin in treating patients who have prostate cancer.
Conditions Studied
Interventions
- DRUG docetaxel
- DRUG doxorubicin hydrochloride
- DRUG warfarin
- DRUG ketoconazole
- DRUG estramustine phosphate sodium
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00014352
The ClinicalTrials.gov registry entry for NCT00014352 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which docetaxel is the first listed.
NCT00014352 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00014352 about?
NCT00014352 is a clinical study titled "Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Anticoagulant drugs such as warfarin may reduce the risk of blood clots. PURPOSE: Phase II trial to study the effectiveness...
What is the current status of trial NCT00014352?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-09.
What conditions does trial NCT00014352 study?
This clinical trial studies the following conditions: Prostate Cancer, Thromboembolism.
What interventions are being tested in trial NCT00014352?
The interventions under investigation include: docetaxel (DRUG), doxorubicin hydrochloride (DRUG), warfarin (DRUG), ketoconazole (DRUG), estramustine phosphate sodium (DRUG).
Who is sponsoring clinical trial NCT00014352?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00014352 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.